...
首页> 外文期刊>Journal of arrhythmia. >Genetics of Brugada syndrome
【24h】

Genetics of Brugada syndrome

机译:Brugada综合征的遗传学

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In 1992, the Brugada syndrome (BrS) was recognized as a disease responsible for sudden cardiac death, characterized by a right bundle-branch block with ST segment elevation in the leads V1 and V2. This syndrome is highly associated with sudden cardiac death, especially in young males. BrS is currently diagnosed in patients with ST-segment elevation showing type 1 morphology >=2 mm in >=1 leads among the right precordial leads V1 or V2 positioned in the 2nd, 3rd, or 4th intercostal space, and occurring either spontaneously or after a provocative drug test by the intravenous administration of Class I antiarrhythmic drugs. With accumulated findings, the BrS inheritance model is believed to be an autosomal dominant inheritable model with incomplete penetrance, although most patients with BrS were sporadic cases. SCN5A, which was identified as the first BrS-associated gene in 1998, has emerged as the most common gene associated with BrS, and more than 10 BrS-associated genes have been identified thereafter. Mutation-specific genetic testing is recommended for the family members and appropriate relatives following the identification of BrS-causative mutations in an index patient. In addition, comprehensive or BrS1 (SCN5A) targeted genetic testing could be useful for patients in whom a cardiologist has established a clinical index of suspicion for BrS based on the patient@?s clinical history, family history, and the expressed electrocardiographic (resting 12-lead ECGs and/or provocative drug challenge testing) phenotype. Over the past 20 years, extensive research in this field has allowed better understanding of the pathophysiology, genetic background, and management of BrS even though controversies still exist. In this review article, a background of genetics, the genetic background of BrS, the genotype and phenotype relationship, the role of genetic screening in clinical practice, and the interpretation of the identified genetic variants have been addressed based on this understanding.
机译:在1992年,Brugada综合征(BrS)被认为是导致心源性猝死的疾病,其特征是V1和V2导联中ST段抬高的右束支传导阻滞。该综合征与心脏猝死高度相关,尤其是在年轻男性中。目前在患有ST段抬高的患者中诊断为BrS,其显示在位于第二,第三或第四肋间隙的右胸前导联V1或V2中的> = 1导联中的> = 1导联中的1型形态> = 2 mm静脉注射I类抗心律不齐药物进行的刺激性药物测试。通过积累的发现,尽管大多数BrS患者是零星病例,但人们认为BrS遗传模型是具有不完全外显性的常染色体显性遗传模型。 SCN5A在1998年被确定为第一个与BrS相关的基因,已成为与BrS相关的最常见基因,此后已鉴定出10多个与BrS相关的基因。建议在确定索引患者中的BrS致突变后,对家庭成员和适当的亲属进行突变特异性基因检测。此外,全面的或BrS1(SCN5A)靶向基因检测对于心脏病专家根据患者的临床病史,家族病史和明确的心电图检查确定了BrS的临床指标的患者可能有用。 -前导心电图和/或刺激性药物挑战测试)表型。在过去的20年中,尽管仍然存在争议,但在该领域的大量研究使人们对BrS的病理生理学,遗传背景和管理有了更好的了解。在这篇综述文章中,基于这种理解,研究了遗传学的背景,BrS的遗传背景,基因型和表型的关系,基因筛选在临床实践中的作用以及对已鉴定的遗传变异的解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号